Using the 21-gene recurrence score and the recently developed Recurrence Score-Clinical-Pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.
M. Crager
Employment or Leadership Position - Genomic Health
G. Tang
No relevant relationships to disclose
S. Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health